# www.protagonist-inc.com Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. ## Pages - [Product Pipeline](http://www.protagonist-inc.com/product-pipeline): Product Pipeline - Protagonist Therapeutics Inc. - [News](http://www.protagonist-inc.com/news): News - Protagonist Therapeutics Inc. - [Stock Info](http://www.protagonist-inc.com/stock-info): Stock Info - Protagonist Therapeutics Inc. - [Press Releases](http://www.protagonist-inc.com/press-releases): Press Releases - Protagonist Therapeutics Inc. - [Publications](http://www.protagonist-inc.com/publications): Publications - Protagonist Therapeutics Inc. - [Executive Team](http://www.protagonist-inc.com/executive-team): Executive Team - Protagonist Therapeutics Inc. - [Careers](http://www.protagonist-inc.com/careers): Careers - Protagonist Therapeutics Inc. - [Terms of Use](http://www.protagonist-inc.com/terms-of-use): Terms of Use - Protagonist Therapeutics Inc. - [Technology](http://www.protagonist-inc.com/technology): Technology - Protagonist Therapeutics Inc. - [Areas of Focus](http://www.protagonist-inc.com/areas-of-focus): Areas of Focus - Protagonist Therapeutics Inc. - [ESG](http://www.protagonist-inc.com/esg): ESG - Protagonist Therapeutics Inc. - [Innovation](http://www.protagonist-inc.com/innovation): Innovation - Protagonist Therapeutics Inc. - [Scientific Posters and Presentations](http://www.protagonist-inc.com/scientific-posters-and-presentations): Scientific Posters & Presentations - Protagonist Therapeutics Inc. - [Governance](http://www.protagonist-inc.com/governance): Governance - Protagonist Therapeutics Inc. - [Community](http://www.protagonist-inc.com/community): Community - Protagonist Therapeutics Inc. - [Leadership](http://www.protagonist-inc.com/leadership): Leadership - Protagonist Therapeutics Inc. - [Investor Contacts](http://www.protagonist-inc.com/investor-contacts): Investor Contacts - Protagonist Therapeutics Inc. - [Financials](http://www.protagonist-inc.com/financials): Financials - Protagonist Therapeutics Inc. - [Blood Cancer Awareness - What You Need to Know Now](http://www.protagonist-inc.com/blood-cancer-awareness-what-you-need-to-know-now): Blood Cancer Awareness - Protagonist Therapeutics Inc. - [Join Our Team](http://www.protagonist-inc.com/join-our-team): Join Our Team - Protagonist Therapeutics Inc. - [Privacy Policy](http://www.protagonist-inc.com/privacy-policy): Privacy Policy - Protagonist Therapeutics Inc. - [Expanded Access Policy](http://www.protagonist-inc.com/expanded-access-policy): Privacy Policy - Protagonist Therapeutics Inc. - [Culture & Values](http://www.protagonist-inc.com/culture-values): Culture & Values - Protagonist Therapeutics Inc. - [Clinical Trials](http://www.protagonist-inc.com/clinical-trials): Clinical Trials - Protagonist Therapeutics Inc. - [Locations](http://www.protagonist-inc.com/locations): Locations - Protagonist Therapeutics Inc. - [Contact](http://www.protagonist-inc.com/contact): Contact - Protagonist Therapeutics Inc. - [Board of Directors](http://www.protagonist-inc.com/board-of-directors): Board of Directors - Protagonist Therapeutics Inc. - [Metabolism Scientific Advisory Board](http://www.protagonist-inc.com/metabolism-scientific-advisory-board): Board of Directors - Protagonist Therapeutics Inc. - [Home](http://www.protagonist-inc.com/) - [Analyst Coverage](http://www.protagonist-inc.com/analyst-coverage): Analyst Coverage - Protagonist Therapeutics Inc. - [Corporate Events & Presentations](http://www.protagonist-inc.com/events-presentations): Events & Presentations - Protagonist Therapeutics Inc. - [Investor Email Alerts](http://www.protagonist-inc.com/investor-email-alerts): Investor Email Alerts - Protagonist Therapeutics Inc. ## Blog Posts - [ICOTYDE® named one of TIME Magazine's Best Inventions of 2026](http://www.protagonist-inc.com/icotyde-named-one-of-time-magazine-s-best-inventions-of-2026): ICOTYDE® named one of TIME Magazine's Best Inventions of 2026 - [VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy](http://www.protagonist-inc.com/verify-a-phase-iii-trial-of-rusfertide-versus-placebo-in-phlebotomy-dependent-patients-with-polycythemia-vera-receiving-standard-of-care-therapy) - [Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis](http://www.protagonist-inc.com/improvements-in-clinical-and-patient-reported-outcomes-and-durability-of-response-with-the-targeted-oral-peptide-icotrokinra-in-adolescents-with-moderate-to-severe-plaque-psoriasis) - [Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings](http://www.protagonist-inc.com/durability-of-response-to-icotrokinra-for-high-impact-site-psoriasis-1-year-iconic-total-findings) - [Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis](http://www.protagonist-inc.com/maintenance-of-response-with-icotrokinra-a-targeted-oral-peptide-for-the-treatment-of-moderate-to-severe-plaque-psoriasis) - [Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis](http://www.protagonist-inc.com/durability-of-response-to-icotrokinra-in-adults-with-moderate-to-severe-plaque-psoriasis) - [Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites](http://www.protagonist-inc.com/safety-of-icotrokinra-through-1-year-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-and-psoriasis-affecting-high-impact-sites-pooled-results-across-the-iconic-lead-iconic-total-and-iconic) - [Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis](http://www.protagonist-inc.com/phase-2-trial-of-icotrokinra-for-patients-with-ulcerative-colitis) - [WSJ: The Peptide Boom That Isn’t About Your Muscles](http://www.protagonist-inc.com/wsj-the-peptide-boom-that-isnt-about-your-muscles) - [Protagonist at the Cantor Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/protagonist-at-the-cantor-global-healthcare-conference) - [Protagonist at the Citi Biopharma Back to School Summit](http://www.protagonist-inc.com/protagonist-at-the-citi-biopharma-back-to-school-summit) - [U.S. FDA Approves MIMRYLO™ (rusfertide)](http://www.protagonist-inc.com/events-presentations/u-s-fda-approves-mimrylotm-rusfertide) - [US FDA Approval of MIMRYLO™(rusfertide) for Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)](http://www.protagonist-inc.com/events-presentations/us-fda-approval-of-mimrylotm-rusfertide-for-treatment-of-erythrocytosis-in-adults-with-polycythemia-vera-pv): US FDA Approval of MIMRYLO™(rusfertide) for Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV) - [2026 European Hematology Association (EHA) Meeting](http://www.protagonist-inc.com/2026-european-hematology-association-eha-meeting) - [Protagonist at the Jefferies Global Healthcare Conference](http://www.protagonist-inc.com/jefferies-global-healthcare-conference) - [CEO Dinesh Patel Joins CNBC’s Fast Money](http://www.protagonist-inc.com/ceo-dinesh-patel-joins-cnbcs-fast-money) - [BioSpace covers ICOTYDE™ FDA Approval](http://www.protagonist-inc.com/news/biospace-covers-icotydetm-fda-approval) - [U.S. FDA Approves ICOTYDE™ (icotrokinra)](http://www.protagonist-inc.com/news/us-fda-approves-icotydetm-icotrokinra) - [Barclays Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/barclays-global-healthcare-conference) - [Barclays 28th Annual Global Healthcare Conference](http://www.protagonist-inc.com/barclays-28th-annual-global-healthcare-conference) - [Citizens Life Sciences Conference](http://www.protagonist-inc.com/citizens-life-sciences-conference) - [Jefferies Biotech on the Beach Summit](http://www.protagonist-inc.com/jefferies-biotech-on-the-beach-summit) - [Leerink Global Healthcare Conference](http://www.protagonist-inc.com/leerink-global-healthcare-conference-miami-fl) - [TD Cowen 46th Annual Health Care Conference; Boston, MA](http://www.protagonist-inc.com/td-cowen-46th-annual-health-care-conference-boston-ma-march-2-4-2026) - [Protagonist CEO Dinesh V. Patel and Chief Discovery Officer Ashok Bhandari Speak with BiotechTV](http://www.protagonist-inc.com/news/protagonist-ceo-dinesh-v-patel-and-chief-discovery-officer-ashok-bhandari-speak-with-biotechtv) - [Protagonist Speaks to BioSpace at #JPM26](http://www.protagonist-inc.com/jpm26-protagonist-has-a-400m-decision-to-make-its-a-no-brainer) - [Protagonist at the J.P. Morgan Healthcare Conference](http://www.protagonist-inc.com/protagonist-at-the-j-p-morgan-healthcare-conference) - [Protagonist at the Evercore Healthcare Conference](http://www.protagonist-inc.com/events-presentations/protagonist-at-the-evercore-healthcare-conference) - [Protagonist at the Citi Global Healthcare Conference](http://www.protagonist-inc.com/protagonist-at-the-citi-global-healthcare-conference) - [TD Cowen Advancements in Obesity Summit](http://www.protagonist-inc.com/events-presentatuions/td-cowen-advancements-in-obesity-summit) - [Protagonist CEO Dinesh V. Patel on our programs and culture of partnering at #Jefferies25](http://www.protagonist-inc.com/news/protagonist-ceo-dinesh-v-patel-on-our-programs-and-culture-of-partnering-at-jefferies25) - [Protagonist at the Jefferies Global Healthcare Conference](http://www.protagonist-inc.com/protagonist-at-the-jefferies-global-healthcare-conference) - [Protagonist at the TD Cowen Immunology & Inflammation Summit](http://www.protagonist-inc.com/events-presentations/td-cowen-immunology-inflammation-summit): Protagonist at TD Cowen Immunology & Inflammation Summit - [PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis](http://www.protagonist-inc.com/ptg-100-an-oral-a4b7-antagonist-peptide-preclinical-development-and-phase-1-and-2a-studies-in-ulcerative-colitis): PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis - [Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers](http://www.protagonist-inc.com/single-and-multiple-dose-pharmacokinetics-and-pharmacodynamics-of-pn-943-a-gastrointestinal-restricted-oral-peptide-antagonist-of-47-in-healthy-volunteers) - [Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial](http://www.protagonist-inc.com/rusfertide-for-the-treatment-of-iron-overload-in-hfe-related-haemochromatosis-an-open-label-multicentre-proof-of-concept-phase-2-trial) - [Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera](http://www.protagonist-inc.com/rusfertide-a-hepcidin-mimetic-for-control-of-erythrocytosis-in-polycythemia-vera) - [Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians](http://www.protagonist-inc.com/contemporary-challenges-in-polycythemia-vera-management-from-the-perspective-of-patients-and-physicians) - [Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study](http://www.protagonist-inc.com/pharmacokinetics-pharmacodynamics-and-tolerability-of-an-aqueous-formulation-of-rusfertide-ptg-300-a-hepcidin-mimetic-in-healthy-volunteers-a-double-blind-first-in-human-study) - [Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers](http://www.protagonist-inc.com/pharmacokinetics-and-pharmacodynamics-of-rusfertide-a-hepcidin-mimetic-following-subcutaneous-administration-of-a-lyophilized-powder-formulation-in-healthy-volunteers) - [Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects.](http://www.protagonist-inc.com/multiple-dose-pharmacokinetics-pharmacodynamics-safety-and-tolerability-of-subcutaneous-rusfertide-a-hepcidin-mimetic-in-healthy-subjects) - [An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis](http://www.protagonist-inc.com/an-oral-interleukin-23-receptor-antagonist-peptide-for-plaque-psoriasis) - [JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans](http://www.protagonist-inc.com/jnj-77242113-a-highly-potent-selective-peptide-targeting-the-il-23-receptor-provides-robust-il-23-pathway-inhibition-upon-oral-dosing-in-rats-and-humans) - [FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis](http://www.protagonist-inc.com/frontier-2-a-phase-2b-long-term-extension-dose-ranging-study-of-oral-jnj-77242113-for-the-treatment-of-moderate-to-severe-plaque-psoriasis) - [Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review.](http://www.protagonist-inc.com/oral-peptide-therapeutics-as-an-emerging-treatment-modality-in-immune-mediated-inflammatory-diseases-a-narrative-review) - [Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling.](http://www.protagonist-inc.com/translational-pharmacokinetics-of-icotrokinra-a-targeted-oral-peptide-that-selectively-blocks-interleukin-23-receptor-and-inhibits-signaling) - [2025 Society For Investigative Dermatology](http://www.protagonist-inc.com/2025-society-for-investigative-dermatology) - [2025 European Academy of Dermatology and Venerology Congress](http://www.protagonist-inc.com/2025-european-academy-of-dermatology-and-venerology-congress) - [63rd American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/63rd-american-society-of-hematology-annual-meeting-and-exposition) - [64th American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/64th-american-society-of-hematology-annual-meeting-and-exposition) - [65th American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/65th-american-society-of-hematology-annual-meeting-and-exposition) - [63rd American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/63rd-american-society-of-hematology-ash-annual-meeting-and-exposition) - [American Society of Clinical Oncology 2022 Annual Meeting](http://www.protagonist-inc.com/american-society-of-clinical-oncology-2022-annual-meeting) - [2022 European Hematology Association (EHA) Meeting](http://www.protagonist-inc.com/2022-european-hematology-association-eha-meeting) - [Society of Hematologic Oncology (SOHO) 2022 Annual Meeting](http://www.protagonist-inc.com/society-of-hematologic-oncology-soho-2022-annual-meeting) - [64th American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/64th-american-society-of-hematology-ash-annual-meeting-and-exposition) - [2023 European Hematology Association (EHA) Meeting](http://www.protagonist-inc.com/2023-european-hematology-association-eha-meeting) - [Society of Hematologic Oncology (SOHO) 2023 Annual Meeting](http://www.protagonist-inc.com/society-of-hematologic-oncology-soho-2023-annual-meeting) - [15th International Congress on Myeloproliferative Neoplasms (MPN Congress)](http://www.protagonist-inc.com/15th-international-congress-on-myeloproliferative-neoplasms-mpn-congress) - [65th American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/65th-american-society-of-hematology-ash-annual-meeting-and-exposition) - [10th Translational Research Conference: Myeloproliferative Neoplasms](http://www.protagonist-inc.com/10th-translational-research-conference-myeloproliferative-neoplasms) - [American Society of Clinical Oncology 2024 Annual Meeting](http://www.protagonist-inc.com/american-society-of-clinical-oncology-2024-annual-meeting) - [2024 European Hematology Association (EHA) Meeting](http://www.protagonist-inc.com/2024-european-hematology-association-eha-meeting) - [2024 American College of Clinical Pharmacology (ACCP) Annual Meeting](http://www.protagonist-inc.com/2024-american-college-of-clinical-pharmacology-accp-annual-meeting) - [16th International Congress on Myeloproliferative Neoplasms (MPN Congress)](http://www.protagonist-inc.com/16th-international-congress-on-myeloproliferative-neoplasms-mpn-congress) - [66th American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/66th-american-society-of-hematology-ash-annual-meeting-and-exposition) - [American Society of Clinical Oncology 2025 Annual Meeting](http://www.protagonist-inc.com/american-society-of-clinical-oncology-2025-annual-meeting) - [MPN Workshop of the Carolinas 2025](http://www.protagonist-inc.com/mpn-workshop-of-the-carolinas-2025) - [Society of Hematologic Oncology (SOHO) 2025 Annual Meeting](http://www.protagonist-inc.com/society-of-hematologic-oncology-soho-2025-annual-meeting) - [Protagonist at the H.C. Wainwright Global Investment Conference](http://www.protagonist-inc.com/h-c-wainwright-global-investment-conference) - [Protagonist at the Citigroup 2025 Biopharma Conference](http://www.protagonist-inc.com/protagonist-at-the-citigroup-2025-biopharma-conference) - [Protagonist Announces Nomination of PN-477, an Oral and Injectable Peptide Development Candidate for Obesity](http://www.protagonist-inc.com/protagonist-announces-nomination-of-pn-477-an-oral-and-injectable-peptide-development-candidate-for-obesity) - [Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate](http://www.protagonist-inc.com/events/protagonist-therapeutics-to-host-conference-call-to-announce-an-oral-obesity-development-candidate) - [Protagonist at the Jefferies Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/protagonist-at-the-jefferies-global-healthcare-conference) - [CEO Dinesh V. Patel Speaks With BiotechTV at #ASCO25](http://www.protagonist-inc.com/news/ceo-dinesh-v-patel-speaks-with-biotechtv-at-asco25) - [Post-ASCO Update: Phase 3 VERIFY Study Results](http://www.protagonist-inc.com/events-presentations/post-asco-update-phase-3-verify-study-results) - [Protagonist at the Jefferies Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-global-healthcare-conference-2025) - [Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025](http://www.protagonist-inc.com/events-presentations/plenary-presentation-on-verify-phase-3-study-with-rusfertide-at-asco-2025) - [Protagonist Therapeutics Is One of Fast Company’s Most Innovative Companies of 2025](http://www.protagonist-inc.com/news/protagonist-therapeutics-is-one-of-fast-companys-most-innovative-companies-of-2025) - [Protagonist Investor Conference Call and Webcast](http://www.protagonist-inc.com/events-presentations/protagonist-investor-conference-call-and-webcast) - [Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide](http://www.protagonist-inc.com/events-presentations/investor-event-with-kol-insights-on-polycythemia-vera-pv-and-the-hepcidin-mimetic-rusfertide) - [Protagonist at the J.P. Morgan 43rd Annual Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jpm-43rd-annual-healthcare-conference): Protagonist at J.P. Morgan 43rd Annual Healthcare Conference - [ASH REVIVE Final Analysis Poster](http://www.protagonist-inc.com/publications/ash-revive-final-analysis-poster) - [Endpoints News: J&J and Protagonist Announce Phase 3 Trial Results for icotrokinra (JNJ-2113, formerly PN-235)](http://www.protagonist-inc.com/news/jj-and-protagonist-announce-phase-3-rial-results-for-icotrokinra) - [Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate](http://www.protagonist-inc.com/events-presenations/protagonist-announces-nomination-of-pn-881-a-potential-best-in-class-oral-peptide-il-17-antagonist-development-candidate) - [Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor](http://www.protagonist-inc.com/news/protagonist-announces-positive-topline-results-from-phase-3-iconic-studies-of-icotrokinra-jnj-2113-a-first-in-class-investigational-targeted-oral-peptide-that-selectively-blocks-the-il-23-receptor) - [Protagonist at the The 66th Annual American Society of Hematology (ASH) Annual Meeting](http://www.protagonist-inc.com/events-presentations/the-66th-annual-american-society-of-hematology-ash-annual-meeting) - [Protagonist at the H.C. Wainwright 26th Annual Global Investment Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-26th-annual-global-investment-conference) - [Nature: JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans](http://www.protagonist-inc.com/news/jnj-77242113-a-highly-potent-selective-peptide-targeting-the-il-23-receptor-provides-robust-il-23-pathway-inhibition-upon-oral-dosing-in-rats-and-humans) - [EHA 2024 Oral Presentation: Updated Long-Term Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Polycythemia Vera Patients](http://www.protagonist-inc.com/events-presentations/eha-2024-oral-presentation-updated-long-term-results-from-the-phase-2-revive-study-investigating-the-hepcidin-mimetic-rusfertide-in-polycythemia-vera-patients): EHA 2024 Oral Presentation: Updated Long-Term Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Polycythemia Vera Patients - [Protagonist at the The Citizens JMP Life Sciences Conference](http://www.protagonist-inc.com/events-presentations/the-citizens-jmp-life-sciences-conference-may-13-2024) - [Protagonist at the Jefferies Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-global-healthcare-conference-june-6-2024) - [Protagonist at the Jefferies Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-global-healthcare-conference) - [Corporate Presentation](http://www.protagonist-inc.com/corporate-presentation) - [Protagonist at the The Citizens JMP Life Sciences Conference](http://www.protagonist-inc.com/events-presentations/the-citizens-jmp-life-sciences-conference) - [Protagonist at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-2nd-annual-autoimmune-inflammatory-disease-virtual-conference) - [6th Annual Guggenheim Healthcare Talks Annual Biotechnology Conference](http://www.protagonist-inc.com/events-presentations/6th-annual-guggenheim-healthcare-talks-annual-biotechnology-conference) - [Protagonist at the 42nd Annual J.P. Morgan Healthcare Conference](http://www.protagonist-inc.com/events-presentations/42nd-annual-j-p-morgan-healthcare-conference-jan-8-2023) - [ASH 2023 Oral Presentation: Durability of Hematocrit Control in Polycythemia Vera With the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results From the REVIVE Study](http://www.protagonist-inc.com/events-presentations/ash-2023-oral-presentation-durability-of-hematocrit-control-in-polycythemia-vera-with-the-first-in-class-hepcidin-mimetic-rusfertide-two-year-follow-up-results-from-the-revive-study) - [ASH 2023 Oral Presentation: Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera](http://www.protagonist-inc.com/events-presentations/ash-2023-oral-presentation-real-world-analysis-of-thromboembolic-event-rates-in-patients-in-the-united-states-with-polycythemia-vera) - [ASH 2023 Poster Presentation: Rusfertide Improves Markers Of Iron Deficiency In Patients With Polycythemia Vera](http://www.protagonist-inc.com/events-presentations/ash-2023-poster-presentation-rusfertide-improves-markers-of-iron-deficiency-in-patients-with-polycythemia-vera) - [ASH 2023 Poster Presentation: Prevalence Of Second Cancers In Patients With Polycythemia Vera (PV): A Retrospective Analysis Of Us Real-World Claims Data](http://www.protagonist-inc.com/events-presentations/ash-2023-poster-presentation-prevalence-of-second-cancers-in-patients-with-polycythemia-vera-pv-a-retrospective-analysis-of-us-real-world-claims-data) - [ASH 2023 Poster Presentation: Iron Restricted Erythropoiesis Under Hepcidin Mimetic Treatment (PN23114) Improves Disease Parameters In A Mouse Model For Sickle Cell Disease](http://www.protagonist-inc.com/events-presentations/ash-2023-poster-presentation-iron-restricted-erythropoiesis-under-hepcidin-mimetic-treatment-pn23114-improves-disease-parameters-in-a-mouse-model-for-sickle-cell-disease) - [Protagonist Therapeutics CEO Dinesh V. Patel on our hepcidin memetic and oral IL-23 program at #ASH23](http://www.protagonist-inc.com/news/protagonist-therapeutics-ceo-on-its-hepcidin-memetic-at-ash23-and-oral-il23-program-in-i-i) - [J&J notebook: Highlights from a day of pipeline and strategy discussion](http://www.protagonist-inc.com/news/j-j-notebook-highlights-from-a-day-of-pipeline-and-strategy-discussion) - [Protagonist at the Jefferies London Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-london-healthcare-conference082b4611) - [Summary of Malignancies Observed Across 5 Phase 2 Open Label Clinical Trials of the Hepcidin Mimetic Rusfertide](http://www.protagonist-inc.com/publications/summary-of-malignancies-observed-across-5-phase-2-open-label-clinical-trials-of-the-hepcidin-mimetic-rusfertide) - [Oral IL 23 Receptor Peptide Antagonist JNJ 2113: The Journey from De Novo Discovery to Phase 3 Clinical Development Program](http://www.protagonist-inc.com/publications/oral-il-23-receptor-peptide-antagonist-jnj-2113-the-journey-from-de-novo-discovery-to-phase-3-clinical-development-program) - [JNJ 77242113 Treatment Induces a Strong Systemic Pharmacodynamic Response Versus Placebo in Serum Samples of Patients With Plaque Psoriasis](http://www.protagonist-inc.com/publications/jnj-77242113-treatment-induces-a-strong-systemic-pharmacodynamic-response-versus-placebo-in-serum-samples-of-patients-with-plaque-psoriasis) - [A Phase 2, Randomized, Placebo Controlled, Dose Ranging Study of Oral JNJ 77242113 for the Treatment of Moderate to Severe Plaque Psoriasis](http://www.protagonist-inc.com/publications/a-phase-2-randomized-placebo-controlled-dose-ranging-study-of-oral-jnj-77242113-for-the-treatment-of-moderate-to-severe-plaque-psoriasis) - [Improving Access to Medicines, Ensuring Diverse Representation](http://www.protagonist-inc.com/news/improving-access-to-medicines-ensuring-diverse-representation) - [Protagonist: Inclusion by the Numbers](http://www.protagonist-inc.com/news/protagonist-inclusion-by-the-numbers) - [Blood Cancer Awareness - What You Need to Know Now](http://www.protagonist-inc.com/news/blood-cancer-awareness-what-you-need-to-know-now) - [Join Our Polycythemia Vera VERIFY Clinical Study](http://www.protagonist-inc.com/news/join-our-polycythemia-vera-verify-clinical-study) - [Cancer Moonshot: How We’re Helping Patients](http://www.protagonist-inc.com/news/cancer-moonshot-how-were-helping-patients) - [Polycythemia Vera: Mechanism of Disease](http://www.protagonist-inc.com/news/polycythemia-vera-mechanism-of-disease) - [CEO Dinesh Patel Talks Culture, Collaboration and Courage](http://www.protagonist-inc.com/news/ceo-dinesh-patel-talks-culture-collaboration-and-courage) - [Formulas for Success from Biotechs that Leaped in Value Despite the Downturn](http://www.protagonist-inc.com/news/formulas-for-success-from-biotechs-that-leaped-in-value-despite-the-downturn) - [Amgen tipped to keep Otezla market share in fight with BMS' Sotyktu, leaving opportunity for J&J](http://www.protagonist-inc.com/news/amgen-tipped-to-keep-otezla-market-share-in-fight-with-bms-sotyktu-leaving-opportunity-for-j-j) - [Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera with the Hepcidin Mimetic, Rusfertide: Blinded Randomizated Withdrawal Results of the Phase 2 Revive Study](http://www.protagonist-inc.com/publications/targeted-therapy-of-uncontrolled-erythrocytosis-in-polycythemia-vera-with-the-hepcidin-mimetic-rusfertide-blinded-randomizated-withdrawal-results-of-the-phase-2-revive-study) - [Protagonist at the H.C. Wainwright 25th Annual Global Investment Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-25th-annual-global-investment-conference) - [Wells Fargo 2023 Healthcare Conference](http://www.protagonist-inc.com/events-presentations/wells-fargo-2023-healthcare-conference) - [Rusfertide in PV (REVIVE) - Late Breaking Oral Presentation June 11, 2023](http://www.protagonist-inc.com/publications/rusfertide-in-pv-revive-late-breaking-oral-presentation-june-11-2023) - [Pharmacokinetic and Pharmacodynamic Effects of Rusfertide In Polycythemia Vera: Results from an Ongoing Phase 2 Study in Patients with Elevated Hematocrit Values](http://www.protagonist-inc.com/publications/pharmacokinetic-and-pharmacodynamic-effects-of-rusfertide-in-polycythemia-vera-results-from-an-ongoing-phase-2-study-in-patients-with-elevated-hematocrit-values) - [Rusfertide (PTG-300) Improves Polycythemia Vera (PV) Related Symptoms in PV Patients](http://www.protagonist-inc.com/publications/rusfertide-ptg-300-improves-polycythemia-vera-pv-related-symptoms-in-pv-patients) - [Protagonist at the Jefferies Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-healthcare-conference-2023) - [2023 World Congress of Dermatology](http://www.protagonist-inc.com/events-presentations/2023-world-congress-of-dermatology) - [First-In-Class Oral Peptide Systemically Targeting The IL-23 Pathway](http://www.protagonist-inc.com/publications/first-in-class-oral-peptide-systemically-targeting-the-il-23-pathway) - [2023 Annual Congress of the European Hematology Association](http://www.protagonist-inc.com/events-presentations/2023-annual-congress-of-the-european-hematology-association) - [Real‑World Treatments and Thrombotic Events in Polycythemia Vera Patients in the USA](http://www.protagonist-inc.com/publications/realworld-treatments-and-thrombotic-events-in-polycythemia-vera-patients-in-the-usa) - [J.P. Morgan 2023 Healthcare Conference Company Presentation](http://www.protagonist-inc.com/events-presentations/j-p-morgan-2023-healthcare-conference-company-presentation) - [ASH 2022 Poster Presentation: Rusfertide analog-PN23114 as a hepcidin mimetic provides efficacy benefits in conjunction with phlebotomy in mouse model for hereditary hemochromatosis](http://www.protagonist-inc.com/ash-2022-poster-presentation-rusfertide-analog-pn23114-as-a-hepcidin-mimetic-provides-efficacy-benefits-in-conjunction-with-phlebotomy-in-mouse-model-for-hereditary-hemochromatosis) - [32nd Annual Piper Sandler Healthcare Conference](http://www.protagonist-inc.com/events-presentations/32nd-annual-piper-sandler-healthcare-conference) - [Raymond James Human Health Innovations Conference](http://www.protagonist-inc.com/events-presentations/raymond-james-human-health-innovations-conference) - [UEG Week](http://www.protagonist-inc.com/events-presentations/ueg-week) - [41st Annual J.P. Morgan Health Care Conference](http://www.protagonist-inc.com/events-presentations/41st-annual-j-p-morgan-health-care-conference) - [Cyclic tetrapeptides via the ring contraction strategy: chemical techniques useful for their identification](http://www.protagonist-inc.com/publications/cyclic-tetrapeptides-via-the-ring-contraction-strategy-chemical-techniques-useful-for-their-identification) - [Library of biphenyl privileged substructures using a safety-catch linker approach](http://www.protagonist-inc.com/publications/library-of-biphenyl-privileged-substructures-using-a-safety-catch-linker-approach) - [Defining scaffold geometries for interacting with proteins: geometrical classification of secondary structure linking regions](http://www.protagonist-inc.com/publications/defining-scaffold-geometries-for-interacting-with-proteins-geometrical-classification-of-secondary-structure-linking-regions) - [Conformational searching using a population-based incremental learning algorithm](http://www.protagonist-inc.com/publications/conformational-searching-using-a-population-based-incremental-learning-algorithm) - [Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo](http://www.protagonist-inc.com/publications/discovery-and-characterization-of-a-potent-interleukin-6-binding-peptide-with-neutralizing-activity-in-vivo) - [Clustering of disulfide-rich peptides provides scaffolds for hit discovery by phage display: application to interleukin-23](http://www.protagonist-inc.com/publications/clustering-of-disulfide-rich-peptides-provides-scaffolds-for-hit-discovery-by-phage-display-application-to-interleukin-23) - [Orally Delivered Peptides for Treatment of Inflammatory Bowel Disease](http://www.protagonist-inc.com/publications/orally-delivered-peptides-for-treatment-of-inflammatory-bowel-disease) - [Oral peptides with dual mu/delta opioid receptor agonist activities are superior to eluxadoline in preclinical models of IBS-D](http://www.protagonist-inc.com/publications/oral-peptides-with-dual-mu-delta-opioid-receptor-agonist-activities-are-superior-to-eluxadoline-in-preclinical-models-of-ibs-d) - [Discovery and Characterization of Novel Oral Peptide Antagonists of Human IL-23 Receptor that are Efficacious in a Rat Model of IBD](http://www.protagonist-inc.com/publications/discovery-and-characterization-of-novel-oral-peptide-antagonists-of-human-il-23-receptor-that-are-efficacious-in-a-rat-model-of-ibd) - [Discovery of Novel Oral Peptide Antagonists of IL-23 Receptor that are Efficacious in Rat Model of IBD](http://www.protagonist-inc.com/publications/discovery-of-novel-oral-peptide-antagonists-of-il-23-receptor-that-are-efficacious-in-rat-model-of-ibd) - [The Biomarker Profile of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor, Tracks with Efficacy in Preclinical Model of IBD](http://www.protagonist-inc.com/publications/the-biomarker-profile-of-ptg-200-an-oral-peptide-antagonist-of-il-23-receptor-tracks-with-efficacy-in-preclinical-model-of-ibd) - [(UEGW 2019) Safety, Tolerability, And Pharmacokinetics Of PTG-200, An Oral Gi-Restricted Peptide Antagonist Of IL-23 Receptor, In Normal Healthy Volunteers](http://www.protagonist-inc.com/publications/uegw-2019-safety-tolerability-and-pharmacokinetics-of-ptg-200-an-oral-gi-restricted-peptide-antagonist-of-il-23-receptor-in-normal-healthy-volunteers) - [(ACG 2019) Safety, Tolerability, and Pharmacokinetics of PTG-200, An Oral GI-Restricted Peptide Antagonist of IL-23 Receptor, In Normal Healthy Volunteers](http://www.protagonist-inc.com/publications/acg-2019-safety-tolerability-and-pharmacokinetics-of-ptg-200-an-oral-gi-restricted-peptide-antagonist-of-il-23-receptor-in-normal-healthy-volunteers) - [Integrin α4β7: Discovery of Gut-Restrictive Oral Peptide Antagonists that are Active in Murine Models of Inflammatory Bowel Disease](http://www.protagonist-inc.com/publications/integrin-47-discovery-of-gut-restrictive-oral-peptide-antagonists-that-are-active-in-murine-models-of-inflammatory-bowel-disease) - [Preclinical Characterization of PTG-100, an Oral α4β7 Integrin Peptide Antagonist for Treatment of Ulcerative Colitis](http://www.protagonist-inc.com/publications/preclinical-characterization-of-ptg-100-an-oral-47-integrin-peptide-antagonist-for-treatment-of-ulcerative-colitis) - [PTG-100, an Oral Peptide Antagonist of Integrin α4β7 that Alters Trafficking of Gut Homing T Cells in Preclinical Animal Models](http://www.protagonist-inc.com/publications/ptg-100-an-oral-peptide-antagonist-of-integrin-47-that-alters-trafficking-of-gut-homing-t-cells-in-preclinical-animal-models) - [Establishing the Human Equivalent Dose for PTG-100, an Oral Peptide Antagonist of Integrin α4β7](http://www.protagonist-inc.com/publications/establishing-the-human-equivalent-dose-for-ptg-100-an-oral-peptide-antagonist-of-integrin-47) - [Safety, Pharmacokinetics and Pharmacodynamics of the Novel Oral Peptide Therapeutic PTG-100 (α4β7 Integrin Antagonist) in Normal Healthy Volunteers](http://www.protagonist-inc.com/publications/safety-pharmacokinetics-and-pharmacodynamics-of-the-novel-oral-peptide-therapeutic-ptg-100-47-integrin-antagonist-in-normal-healthy-volunteers) - [Pharmacokinetics and Pharmacodynamics Following Oral Administration Of PTG-100, a Peptide Antagonist of Integrin α4β7](http://www.protagonist-inc.com/publications/pharmacokinetics-and-pharmacodynamics-following-oral-administration-of-ptg-100-a-peptide-antagonist-of-integrin-47) - [Model Based Predictions of the PTG-100 Pharmacodynamic Responses in Ulcerative Colitis Patients](http://www.protagonist-inc.com/publications/model-based-predictions-of-the-ptg-100-pharmacodynamic-responses-in-ulcerative-colitis-patients) - [PTG-100, an Oral Gut-Restricted Peptide α4β7 Antagonist, Induces Clinical and Histologic Remission in Patients with Moderate to Severely Active Ulcerative Colitis](http://www.protagonist-inc.com/publications/ptg-100-an-oral-gut-restricted-peptide-47-antagonist-induces-clinical-and-histologic-remission-in-patients-with-moderate-to-severely-active-ulcerative-colitis) - [The Oral α4β7 Integrin Specific Antagonist PN-10943 is More Effective than PTG-100 in Multiple Preclinical Studies](http://www.protagonist-inc.com/publications/the-oral-47-integrin-specific-antagonist-pn-10943-is-more-effective-than-ptg-100-in-multiple-preclinical-studies) - [PN-943, an Oral α4β7 Integrin Antagonist, Inhibits MAdCAM1-Mediated Proliferation and Cytokine Release from CD4+ T-Cells Independent of Trafficking](http://www.protagonist-inc.com/publications/pn-943-an-oral-47-integrin-antagonist-inhibits-madcam1-mediated-proliferation-and-cytokine-release-from-cd4--t-cells-independent-of-trafficking) - [Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers](http://www.protagonist-inc.com/publications/single-and-multiple-dose-pharmacokinetics-and-pharmacodynamics-of-pn-943-a-gastrointestinal-restricted-oral-peptide-antagonist-of-47-in-healthy-volunteers) - [A Phase 2 randomized, double-blind, placebocontrolled, multi-center study to evaluate the safety and efficacy of the oral, gut-restricted ɑ4β7 integrin peptide antagonist PN-943](http://www.protagonist-inc.com/publications/a-phase-2-randomized-double-blind-placebocontrolled-multi-center-study-to-evaluate-the-safety-and-efficacy-of-the-oral-gut-restricted-47-integrin-peptide-antagonist-pn-943) - [Hepcidin Mimetic PTG-300 for Treatment of Ineffective Erythropoiesis and Iron Overload](http://www.protagonist-inc.com/publications/hepcidin-mimetic-ptg-300-for-treatment-of-ineffective-erythropoiesis-and-iron-overload) - [Hepcidin Mimetic PTG-300 for Treatment of Ineffective Erythropoiesis and Iron Overload Diseases](http://www.protagonist-inc.com/publications/hepcidin-mimetic-ptg-300-for-treatment-of-ineffective-erythropoiesis-and-iron-overload-diseases) - [Hepcidin Mimetic PTG-300 for Treatment of Ineffective Erythropoiesis and Chronic Anemia in Hemoglobinopathy Diseases](http://www.protagonist-inc.com/publications/hepcidin-mimetic-ptg-300-for-treatment-of-ineffective-erythropoiesis-and-chronic-anemia-in-hemoglobinopathy-diseases) - [Hepcidin Mimetic PTG-300 Induces Dose-Related and Sustained Reductions in Serum Iron and Transferrin Saturation in Healthy Subjects](http://www.protagonist-inc.com/publications/hepcidin-mimetic-ptg-300-induces-dose-related-and-sustained-reductions-in-serum-iron-and-transferrin-saturation-in-healthy-subjects) - [Regulation of Iron Homeostasis By PTG-300 Improves Disease Parameters in Mouse Models for Beta-Thalassemia and Hereditary Hemochromatosis](http://www.protagonist-inc.com/publications/regulation-of-iron-homeostasis-by-ptg-300-improves-disease-parameters-in-mouse-models-for-beta-thalassemia-and-hereditary-hemochromatosis) - [Mechanism of Systemic Iron Regulation and Hematocrit Control By Hepcidin Peptidomimetics in Pre-Clinical Models](http://www.protagonist-inc.com/publications/mechanism-of-systemic-iron-regulation-and-hematocrit-control-by-hepcidin-peptidomimetics-in-pre-clinical-models-nov-2020) - [PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients](http://www.protagonist-inc.com/publications/ptg-300-eliminates-the-need-for-therapeutic-phlebotomy-in-both-low-and-high-risk-polycythemia-vera-patients-dec-2020) - [Hepcidin Peptidomimetics – Oral Efficacy in Pre-Clinical Disease Models of Iron Overload and Erythrocytosis](http://www.protagonist-inc.com/publications/hepcidin-peptidomimetics-oral-efficacy-in-pre-clinical-disease-models-of-iron-overload-and-erythrocytosis) - [PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients](http://www.protagonist-inc.com/publications/ptg-300-eliminates-the-need-for-therapeutic-phlebotomy-in-both-low-and-high-risk-polycythemia-vera-patients) - [Regulation of Iron Homeostasis by PTG-300 Improves Disease Parameters in Mouse Models for Beta-Thalassemia & Hereditary Hemochromatosis](http://www.protagonist-inc.com/publications/regulation-of-iron-homeostasis-by-ptg-300-improves-disease-parameters-in-mouse-models-for-beta-thalassemia-hereditary-hemochromatosis) - [Mechanism of Systemic Iron Regulation and Hematocrit Control By Hepcidin Peptidomimetics in Pre-Clinical Models](http://www.protagonist-inc.com/publications/mechanism-of-systemic-iron-regulation-and-hematocrit-control-by-hepcidin-peptidomimetics-in-pre-clinical-models) - [Hepcidin Peptidomimetics - Oral Efficacy in Pre-Clinical Disease Models for Iron Overload and Erythrocytosis](http://www.protagonist-inc.com/publications/hepcidin-peptidomimetics-oral-efficacy-in-pre-clinical-disease-models-for-iron-overload-and-erythrocytosis) - [The Hepcidin Mimetic Rusfertide as a Treatment for Hereditary Hemochromatosis](http://www.protagonist-inc.com/publications/the-hepcidin-mimetic-rusfertide-as-a-treatment-for-hereditary-hemochromatosis) - [PTG-300 (Rusfertide) Treatment Interruption Reverses Hematological Gains And Restores Therapeutic Benefit On Reinitiation In Subjects With Polycythemia Vera](http://www.protagonist-inc.com/publications/ptg-300-rusfertide-treatment-interruption-reverses-hematological-gains-and-restores-therapeutic-benefit-on-reinitiation-in-subjects-with-polycythemia-vera) - [Rusfertide for Polycythemia Vera: Similar Dosing in Patients Receiving Therapeutic Phlebotomy Alone or in Combination with Cytoreductive Treatment](http://www.protagonist-inc.com/publications/rusfertide-for-polycythemia-vera-similar-dosing-in-patients-receiving-therapeutic-phlebotomy-alone-or-in-combination-with-cytoreductive-treatment) - [Subgroup Analysis of Adverse Events Following Rusfertide Dosing in REVIVE: A Phase 2 Study in Patients with Polycythemia Vera](http://www.protagonist-inc.com/publications/subgroup-analysis-of-adverse-events-following-rusfertide-dosing-in-revive-a-phase-2-study-in-patients-with-polycythemia-vera) - [BMO Capital Markets, Prescriptions for Success Healthcare Conference](http://www.protagonist-inc.com/events-presentations/bmo-capital-markets-prescriptions-for-success-healthcare-conference) - [2016 Advances in Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation of America’s Clinical & Research Conference](http://www.protagonist-inc.com/events-presentations/2016-advances-in-inflammatory-bowel-diseases-crohns-colitis-foundation-of-americas-clinical-research-conference) - [BioEurope 2016](http://www.protagonist-inc.com/events-presentations/bioeurope-2016) - [Protagonist Therapeutics Inc at 252nd American Chemical Society National Meeting & Exposition](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-at-252nd-american-chemical-society-national-meeting-exposition) - [BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference](http://www.protagonist-inc.com/events-presentations/bmo-capital-markets-2017-prescriptions-for-success-healthcare-conference) - [Protagonist Therapeutics Inc at Stifel 2017 Healthcare Conference](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-at-stifel-2017-healthcare-conference) - [2017 Cantor Fitzgerald Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/2017-cantor-fitzgerald-global-healthcare-conference) - [Protagonist Business Update](http://www.protagonist-inc.com/events-presentations/protagonist-business-update) - [Annual Meeting of Stockholders](http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-may-25-2017) - [Digestive Diseases Week](http://www.protagonist-inc.com/events-presentations/digestive-diseases-week) - [Oxford Global’s 4th Annual Peptide Congress](http://www.protagonist-inc.com/events-presentations/oxford-globals-4th-annual-peptide-congress) - [Drug Discovery Chemistry](http://www.protagonist-inc.com/events-presentations/drug-discovery-chemistry) - [Oppenheimer & Co. Healthcare Conference](http://www.protagonist-inc.com/events-presentations/oppenheimer-co-healthcare-conference) - [Barclays Global Healthcare Conference 2017](http://www.protagonist-inc.com/events-presentations/barclays-global-healthcare-conference-2017) - [Leerink Partners 6th Annual Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/leerink-partners-6th-annual-global-healthcare-conference) - [12th Congress of ECCO (European Crohn's and Colitis Organization)](http://www.protagonist-inc.com/events-presentations/12th-congress-of-ecco-european-crohn-s-and-colitis-organization) - [BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference](http://www.protagonist-inc.com/events-presentations/bmo-capital-markets-2018-prescriptions-for-success-healthcare-conference) - [Protagonist Corporate Update Call](http://www.protagonist-inc.com/events-presentations/protagonist-corporate-update-call-2018) - [United European Gastroenterology Week Meeting](http://www.protagonist-inc.com/events-presentations/united-european-gastroenterology-week-meeting) - [Cantor Fitzgerald Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/cantor-fitzgerald-global-healthcare-conference) - [PROPEL Study and PTG-100 Program Update Conference Call](http://www.protagonist-inc.com/events-presentations/propel-study-and-ptg-100-program-update-conference-call) - [2018 JMP Securities Life Sciences Conference](http://www.protagonist-inc.com/events-presentations/2018-jmp-securities-life-sciences-conference) - [Hepcidin mimetic PTG-300 for treatment of ineffective erythropoiesis and chronic anemia in hemoglobinopathy diseases](http://www.protagonist-inc.com/events-presentations/hepcidin-mimetic-ptg-300-for-treatment-of-ineffective-erythropoiesis-and-chronic-anemia-in-hemoglobinopathy-diseases) - [Hepcidin Mimetic PTG-300 induces dose-related and sustained reductions in serum iron and transferrin saturation in healthy subjects](http://www.protagonist-inc.com/events-presentations/hepcidin-mimetic-ptg-300-induces-dose-related-and-sustained-reductions-in-serum-iron-and-transferrin-saturation-in-healthy-subjects) - [23rd Congress of the European Hematology Association (EHA)](http://www.protagonist-inc.com/events-presentations/23rd-congress-of-the-european-hematology-association-eha) - [Digestive Diseases Week® (DDW) Conference](http://www.protagonist-inc.com/events-presentations/digestive-diseases-week-ddw-conference) - [Annual Meeting of Stockholders](http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-may-29-2018) - [Protagonist Therapeutics Inc Conference Call](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-conference-call) - [Protagonist Therapeutics Inc at 28th Annual Oppenheimer Healthcare Conference](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-at-28th-annual-oppenheimer-healthcare-conference) - [Protagonist Therapeutics Inc at Barclay's Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-at-barclay-s-global-healthcare-conference) - [Protagonist Therapeutics, Inc. 2017 Year-End Update Call](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-2017-year-end-update-call) - [BTIG’s 2018 Healthcare Conference](http://www.protagonist-inc.com/events-presentations/btigs-2018-healthcare-conference) - [Leerink Partners 7th Annual Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/leerink-partners-7th-annual-global-healthcare-conference) - [Piper Healthcare Conference](http://www.protagonist-inc.com/events-presentations/piper-healthcare-conference) - [PTG-300 beta-thalassemia update](http://www.protagonist-inc.com/events-presentations/ptg-300-beta-thalassemia-update) - [Stifel 2019 Healthcare Conference](http://www.protagonist-inc.com/events-presentations/stifel-2019-healthcare-conference) - [Cantor Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/cantor-global-healthcare-conference) - [Protagonist at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-co-2019-annual-healthcare-conference) - [BMO 2019 Prescription for Success Healthcare Conference](http://www.protagonist-inc.com/events-presentations/bmo-2019-prescription-for-success-healthcare-conference) - [Annual Meeting of Stockholders](http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-jun-7-2019) - [Digestive Disease Week (DDW)](http://www.protagonist-inc.com/events-presentations/digestive-disease-week-ddw) - [Protagonist Corporate Update Call](http://www.protagonist-inc.com/events-presentations/protagonist-corporate-update-call-may-8-2019) - [Protagonist at the H.C. Wainwright & Co. Global Life Sciences Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-co-global-life-sciences-conference) - [Q4 2018 Protagonist Therapeutics Inc Earnings Conference Call](http://www.protagonist-inc.com/events-presentations/q4-2018-protagonist-therapeutics-inc-earnings-conference-call) - [Leerink Partners 8th Annual Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/leerink-partners-8th-annual-global-healthcare-conference) - [Research and Development (R&D) and Corporate Update](http://www.protagonist-inc.com/events-presentations/research-and-development-r-d-and-corporate-update) - [62nd ASH Annual Meeting and Exposition](http://www.protagonist-inc.com/events-presentations/62nd-ash-annual-meeting-and-exposition) - [Protagonist at the Jefferies London Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-london-healthcare-conference-2020) - [Protagonist at the H.C. Wainwright 22nd Annual Global Investment Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-22nd-annual-global-investment-conference) - [Protagonist at the Jefferies Next Generation IBD Therapeutics Virtual Summit](http://www.protagonist-inc.com/events-presentations/jefferies-next-generation-ibd-therapeutics-virtual-summit) - [Protagonist Therapeutics PTG-300 Opportunity Update Webinar](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-ptg-300-opportunity-update-webinar) - [BMO Prescriptions for Success Healthcare Conference](http://www.protagonist-inc.com/events-presentations/bmo-prescriptions-for-success-healthcare-conference) - [Protagonist at the Jefferies Virtual Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-virtual-healthcare-conference-jun-3-2020) - [Annual Meeting of Stockholders](http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-may-28-2020) - [Protagonist Corporate and R&D Update Call](http://www.protagonist-inc.com/events-presentations/protagonist-corporate-and-r-d-update-call) - [Protagonist Therapeutics 2019 Year-End Update Call](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-2019-year-end-update-call) - [SVB Leerink Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/svb-leerink-global-healthcare-conference) - [ASH 2021 Presentation](http://www.protagonist-inc.com/events-presentations/ash-2021-presentation) - [JMP Securities Hematology and Oncology Summit - 1:40 PM ET](http://www.protagonist-inc.com/events-presenations/jmp-securities-hematology-and-oncology-summit-1-40-pm-et) - [Piper Sandler 33rd Annual Healthcare Conference](http://www.protagonist-inc.com/events-presentations/piper-sandler-33rd-annual-healthcare-conference) - [Protagonist at the Jefferies London Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-london-healthcare-conference) - [The Liver Meeting®: AASLD 2021 Oral Presentation](http://www.protagonist-inc.com/events-presentations/the-liver-meeting-aasld-2021-oral-presentation) - [Protagonist at the Jefferies Next Generation IBD Therapeutics Summit](http://www.protagonist-inc.com/events-presentations/jefferies-next-generation-ibd-therapeutics-summit) - [Protagonist Regulatory Update Conference Call](http://www.protagonist-inc.com/events-presentations/protagonist-regulatory-update-conference-call) - [Investor Call on Updated Janssen Agreement](http://www.protagonist-inc.com/events-presentations/investor-call-on-updated-janssen-agreement) - [European Hematology Association ("EHA") 2021 Annual Congress](http://www.protagonist-inc.com/events-presentations/european-hematology-association-eha-2021-annual-congress) - [EHA2021 Corporate Event: Conference Call and Webcast](http://www.protagonist-inc.com/events-presentations/eha2021-corporate-event-conference-call-and-webcast) - [Protagonist at the Jefferies Virtual Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-virtual-healthcare-conference) - [Annual Meeting of Stockholders](http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-2021) - [Protagonist Corporate Update Call](http://www.protagonist-inc.com/events-presentations/protagonist-corporate-update-call) - [Protagonist Therapeutics Fourth Quarter and Year-end Financial Results](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-fourth-quarter-and-year-end-financial-results) - [Protagonist at the H.C. Wainwright Global Life Sciences Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-global-life-sciences-conference) - [10th Annual SVB Leerink Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/10th-annual-svb-leerink-global-healthcare-conference) - [39th Annual J.P. Morgan Healthcare Conference](http://www.protagonist-inc.com/events-presentations/39th-annual-j-p-morgan-healthcare-conference) - [Protagonist at the H.C. Wainwright BioConnect 2022 Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-bioconnect-2022-conference) - [40th Annual J.P. Morgan Healthcare Conference](http://www.protagonist-inc.com/events-presentations/40th-annual-j-p-morgan-healthcare-conference) - [11th Annual SVB Leerink Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/11th-annual-svb-leerink-global-healthcare-conference) - [PN-943 Phase 2 Data Readout – Conference Call](http://www.protagonist-inc.com/events-presentations/pn-943-phase-2-data-readout-conference-call) - [IDEAL PN-943 DDW 2022 Presentation](http://www.protagonist-inc.com/events-presentations/ideal-pn-943-ddw-2022-presentation) - [Annual Meeting of Stockholders](http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders) - [ASCO 2022 Presentation](http://www.protagonist-inc.com/events-presentations/asco-2022-presentation) - [Protagonist at the Jefferies Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-healthcare-conference) - [EHA 2022 Poster Presentation](http://www.protagonist-inc.com/events-presentations/eha-2022-poster-presentation) - [California Life Sciences Cancer Moonshot](http://www.protagonist-inc.com/events-presentations/california-life-sciences-cancer-moonshot) - [SOHO Rusfertide Presentation](http://www.protagonist-inc.com/events-presentations/soho-rusfertide-presentation) - [ASH 2022 Poster Presentation: VERIFY: A Phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera](http://www.protagonist-inc.com/events-presentations/ash-2022-poster-presentation-dec-10-2022) - [ASH Annual Meeting & Exposition](http://www.protagonist-inc.com/events-presentations/ash-annual-meeting-exposition) - [ASH 2022 Poster Presentation: Subgroup analysis of Adverse Events following rusfertide dosing in REVIVE: A Phase 2 study in patients with polycythemia vera](http://www.protagonist-inc.com/events-presentations/ash-2022-poster-presentation)